Clinical Trial Update: Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating senicapoc in patients with worsening fibrotic interstitial lung disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis
• Interstitial Lung Disease

Drugs mentioned

• Senicapoc (senicapoc)

Snippet

Sponsor: Vejle Hospital | Conditions: Pulmonary Fibrosis, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis | Phase 2 | Status: RECRUITING